Ask AI
ProCE Banner Activity

FORTITUDE-101: Bemarituzumab + mFOLFOX6 vs Placebo + mFOLFOX6 in Patients With Advanced/Metastatic FGFR2b  -Overexpressing G/GEJ Cancer

Conference Coverage
Slideset

In the analysis of the phase III FORTITUDE-101 trial, addition of bemarituzumab vs placebo to mFOLFOX6 improved overall survival and progression-free survival in patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction adenocarcinoma.

Released: November 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly